1
|
Fauquembergue L, Le Guen V, Badreau M, Gilbert F, Descatha A. Matrices secteurs-inaptitudes et handicap à la Réunion : de la description, la prédiction par Machine Learning à la prévention de la désinsertion professionnelle. ARCH MAL PROF ENVIRO 2023. [DOI: 10.1016/j.admp.2022.101705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
|
2
|
Rubion E, Fouquet N, Gilbert F, Roquelaure Y. Fractions de risque attribuable aux douleurs chroniques ou intenses de l’épaule en France à partir de la cohorte Constances. ARCH MAL PROF ENVIRO 2022. [DOI: 10.1016/j.admp.2022.10.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
3
|
Sevin F, Naidati A, Miganeh Hadi S, Perez C, Maugeais M, Lahrach M, Gilbert F, Pradeau C, Lesaine E. Traitement automatisé des textes médicaux pour le repérage des patients dans un registre. Rev Epidemiol Sante Publique 2022. [DOI: 10.1016/j.respe.2022.06.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022] Open
|
4
|
Stevens I, Gilbert F. International Regulatory Standards for the Qualitative Measurement of Deep Brain Stimulation in Clinical Research. J Empir Res Hum Res Ethics 2022; 17:228-241. [DOI: 10.1177/15562646221094922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Deep brain stimulation (DBS) has progressed to become a promising treatment modality for neurologic and psychiatric disorders like epilepsy and major depressive disorder due to its growing personalization. Despite evidence pointing to the benefits of DBS if tested on these personalized qualitative metrics, rather than randomized-control trial quantitative standards, the evaluation of these novel devices appears to be based on the latter. This study surveyed the presence of this trend in the national regulatory guidelines of the prominent DBS researching countries. It was found that two governing bodies, in the European Union and Australia, acknowledged the option for qualitative measures. These findings support further development of national regulatory guidelines, so the neuroscientific community developing these neurotechnologies can better understand the impact their treatments have on patients.
Collapse
Affiliation(s)
- I. Stevens
- School of Humanities, University of Tasmania, Hobart, Tasmania, Australia
| | - F. Gilbert
- School of Humanities, University of Tasmania, Hobart, Tasmania, Australia
| |
Collapse
|
5
|
Monaghan O, O’Dwyer N, Dunne M, Nugent J, Coughlan N, Nolan A, Gilbert F, Glynn A, Duane F, Parkes C, Brennan S. PO-0967 Factors associated with feeding tube requirement in Oropharyngeal Cancer treated with IMRT. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07418-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
6
|
Thevenet V, Maugeais M, Lesaine E, Miganeh Hadi S, Gilbert F, Rouanet F, Sibon I, Saillour-Glénisson F. Prise en charge hospitalière des infarctus cérébraux : lien entre caractéristiques structurelles des établissements de santé et délais intrahospitaliers. Rev Epidemiol Sante Publique 2021. [DOI: 10.1016/j.respe.2021.04.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
7
|
Sevin F, Gilbert F, Domecq S, Jouson D, Lesaine E, Saillour-Glenisson F. Mise en place du système d’information régional de l’Observatoire des accidents vasculaires cérébraux en Nouvelle-Aquitaine (ObA2-NA). Rev Epidemiol Sante Publique 2020. [DOI: 10.1016/j.respe.2020.03.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
8
|
Domecq S, Saillour-Glénisson F, Lesaine E, Gilbert F, Maugeais M, Rouanet F. Description des délais de prise en charge des patients victimes d’un accident vasculaire cérébral entre l’apparition des symptômes et le traitement dans 11 établissements de santé entre 2012 et 2019 en ex-Aquitaine. Rev Epidemiol Sante Publique 2020. [DOI: 10.1016/j.respe.2020.03.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
9
|
Schmalzl J, Plumhoff P, Gilbert F, Gohlke F, Konrads C, Brunner U, Jakob F, Ebert R, Steinert AF. The inflamed biceps tendon as a pain generator in the shoulder: A histological and biomolecular analysis. J Orthop Surg (Hong Kong) 2020; 27:2309499018820349. [PMID: 30739571 DOI: 10.1177/2309499018820349] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
INTRODUCTION The long head of the biceps (LHB) is often resected in shoulder surgery. However, its contribution to inflammatory processes in the shoulder remains unclear. In the present study, inflamed and noninflamed human LHBs were comparatively characterized for features of inflammation. MATERIALS AND METHODS Twenty-two resected LHB tendons were classified into inflamed ( n = 11) and noninflamed ( n = 11) samples. For histological examination, samples were stained with hematoxylin eosin, Azan, van Gieson, and Masson Goldner trichrome. Neuronal tissue was immunohistochemically visualized. In addition, specific inflammatory marker gene expression of primary LHB-derived cell cultures were analyzed. RESULTS Features of tendinopathy, such as collagen disorganization, infiltration by inflammatory cells, neovascularization, and extensive neuronal innervation were found in the tendinitis group. Compared to noninflamed samples, inflamed LHBs showed a significantly increased inflammatory marker gene expression. CONCLUSION Structural and biomolecular differences of both groups suggest that the LHB tendon acts as an important pain generator in the shoulder joint. These findings can, on the one hand, contribute to the understanding of the biomolecular genesis of LHB tendinitis and, on the other hand, provide possibilities for new therapeutic approaches.
Collapse
Affiliation(s)
- J Schmalzl
- 1 Department of Orthopaedic Surgery, Julius Maximilians University of Wuerzburg, Wuerzburg, Germany.,2 Department of Traumatology and Hand Surgery, St. Vincentius Clinic, Suedendstraße Karlsruhe, Germany
| | - P Plumhoff
- 1 Department of Orthopaedic Surgery, Julius Maximilians University of Wuerzburg, Wuerzburg, Germany
| | - F Gilbert
- 1 Department of Orthopaedic Surgery, Julius Maximilians University of Wuerzburg, Wuerzburg, Germany.,3 Department of Trauma, Hand, Plastic and Reconstructive Surgery, University Hospital of Wuerzburg, Wuerzburg, Germany
| | - F Gohlke
- 1 Department of Orthopaedic Surgery, Julius Maximilians University of Wuerzburg, Wuerzburg, Germany.,4 Clinic for Shoulder Surgery, Rhoen Klinikum AG, Bad Neustadt/Saale, Germany
| | - C Konrads
- 1 Department of Orthopaedic Surgery, Julius Maximilians University of Wuerzburg, Wuerzburg, Germany
| | - U Brunner
- 5 Department of Orthopaedic and Trauma Surgery, Norbert-Kerkel-Platz, Krankenhaus Agatharied GmbH, Hausham, Germany
| | - F Jakob
- 1 Department of Orthopaedic Surgery, Julius Maximilians University of Wuerzburg, Wuerzburg, Germany
| | - R Ebert
- 1 Department of Orthopaedic Surgery, Julius Maximilians University of Wuerzburg, Wuerzburg, Germany
| | - A F Steinert
- 1 Department of Orthopaedic Surgery, Julius Maximilians University of Wuerzburg, Wuerzburg, Germany.,5 Department of Orthopaedic and Trauma Surgery, Norbert-Kerkel-Platz, Krankenhaus Agatharied GmbH, Hausham, Germany
| |
Collapse
|
10
|
Domecq S, Saillour-Glenisson F, Lesaine E, Gilbert F, Maugeais M, Rouanet F. Description des délais de prise en charge des patients victimes d’un accident vasculaire cérébral entre l’apparition des symptômes et le traitement dans six établissements de santé aquitains entre 2012 et 2017. Rev Epidemiol Sante Publique 2020. [DOI: 10.1016/j.respe.2020.01.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
11
|
Weissenberger M, Weissenberger MH, Gilbert F, Groll J, Evans CH, Steinert AF. Reduced hypertrophy in vitro after chondrogenic differentiation of adult human mesenchymal stem cells following adenoviral SOX9 gene delivery. BMC Musculoskelet Disord 2020; 21:109. [PMID: 32066427 PMCID: PMC7026978 DOI: 10.1186/s12891-020-3137-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/01/2019] [Accepted: 02/12/2020] [Indexed: 01/03/2023] Open
Abstract
Background Mesenchymal stem cell (MSC) based-treatments of cartilage injury are promising but impaired by high levels of hypertrophy after chondrogenic induction with several bone morphogenetic protein superfamily members (BMPs). As an alternative, this study investigates the chondrogenic induction of MSCs via adenoviral gene-delivery of the transcription factor SOX9 alone or in combination with other inducers, and comparatively explores the levels of hypertrophy and end stage differentiation in a pellet culture system in vitro. Methods First generation adenoviral vectors encoding SOX9, TGFB1 or IGF1 were used alone or in combination to transduce human bone marrow-derived MSCs at 5 × 102 infectious particles/cell. Thereafter cells were placed in aggregates and maintained for three weeks in chondrogenic medium. Transgene expression was determined at the protein level (ELISA/Western blot), and aggregates were analysed histologically, immunohistochemically, biochemically and by RT-PCR for chondrogenesis and hypertrophy. Results SOX9 cDNA was superior to that encoding TGFB1, the typical gold standard, as an inducer of chondrogenesis in primary MSCs as evidenced by improved lacuna formation, proteoglycan and collagen type II staining, increased levels of GAG synthesis, and expression of mRNAs associated with chondrogenesis. Moreover, SOX9 modified aggregates showed a markedly lower tendency to progress towards hypertrophy, as judged by expression of the hypertrophy markers alkaline phosphatase, and collagen type X at the mRNA and protein levels. Conclusion Adenoviral SOX9 gene transfer induces chondrogenic differentiation of human primary MSCs in pellet culture more effectively than TGFB1 gene transfer with lower levels of chondrocyte hypertrophy after 3 weeks of in vitro culture. Such technology might enable the formation of more stable hyaline cartilage repair tissues in vivo.
Collapse
Affiliation(s)
- M Weissenberger
- Department of Orthopaedic Surgery, König-Ludwig-Haus, Center for Musculoskeletal Research, Julius-Maximilians-University, Brettreichstrasse 11, D-97074, Würzburg, Germany.
| | - M H Weissenberger
- Department of Orthopaedic Surgery, König-Ludwig-Haus, Center for Musculoskeletal Research, Julius-Maximilians-University, Brettreichstrasse 11, D-97074, Würzburg, Germany.,Department of Pathology, Caritas-Hospital, Bad Mergentheim, Germany
| | - F Gilbert
- Department of Orthopaedic Surgery, König-Ludwig-Haus, Center for Musculoskeletal Research, Julius-Maximilians-University, Brettreichstrasse 11, D-97074, Würzburg, Germany.,Department of Orthopaedic Trauma, Hand, Plastic and Reconstructive Surgery, University Hospital Würzburg, Würzburg, Germany
| | - J Groll
- Department of Functional Materials in Medicine and Dentistry, Julius-Maximilians-University, Würzburg, Germany
| | - C H Evans
- Rehabilitation Medicine Research Center, Mayo Clinic, Rochester, MN, USA
| | - A F Steinert
- Department of Orthopaedic Surgery, König-Ludwig-Haus, Center for Musculoskeletal Research, Julius-Maximilians-University, Brettreichstrasse 11, D-97074, Würzburg, Germany.,Present address: Department of Orthopaedic, Trauma, Shoulder and Arthroplasty Surgery, Rhön-Klinikum Campus Bad Neustadt, Bad Neustadt a.d. Saale, Germany
| |
Collapse
|
12
|
Affiliation(s)
- F Gilbert
- Centre for Neurotechnology, University of Washington, Seattle, USA
- School of Humanities, CALE, University of Tasmania, Hobart, Australia
| | - C Pham
- Centre for Neurotechnology, University of Washington, Seattle, USA
| | - Jnm Viaña
- School of Humanities, CALE, University of Tasmania, Hobart, Australia
| | - W. Gillam
- Centre for Neurotechnology, University of Washington, Seattle, USA
| |
Collapse
|
13
|
Gilbert F, Cook M, O’Brien T, Illes J. Embodiment and Estrangement: Results from a First-in-Human "Intelligent BCI" Trial. Sci Eng Ethics 2019; 25:83-96. [PMID: 29129011 PMCID: PMC6418065 DOI: 10.1007/s11948-017-0001-5] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/02/2017] [Accepted: 10/31/2017] [Indexed: 05/21/2023]
Abstract
While new generations of implantable brain computer interface (BCI) devices are being developed, evidence in the literature about their impact on the patient experience is lagging. In this article, we address this knowledge gap by analysing data from the first-in-human clinical trial to study patients with implanted BCI advisory devices. We explored perceptions of self-change across six patients who volunteered to be implanted with artificially intelligent BCI devices. We used qualitative methodological tools grounded in phenomenology to conduct in-depth, semi-structured interviews. Results show that, on the one hand, BCIs can positively increase a sense of the self and control; on the other hand, they can induce radical distress, feelings of loss of control, and a rupture of patient identity. We conclude by offering suggestions for the proactive creation of preparedness protocols specific to intelligent-predictive and advisory-BCI technologies essential to prevent potential iatrogenic harms.
Collapse
Affiliation(s)
- F. Gilbert
- Centre for Sensorimotor Neural Engineering, Department of Philosophy, University of Washington, Seattle, WA USA
- National Core for Neuroethics, Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC USA
- Australian Research Council DECRA Fellow, University of Tasmania, Hobart, Australia
| | - M. Cook
- Department of Medicine, The Royal Melbourne Hospital, University of Melbourne, Parkville, Australia
- Department of Neurology, St. Vincent’s Hospital, Melbourne, Australia
| | - T. O’Brien
- Department of Medicine, The Royal Melbourne Hospital, University of Melbourne, Parkville, Australia
| | - J. Illes
- National Core for Neuroethics, Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC USA
| |
Collapse
|
14
|
Gilbert F, Schneemann C, Scholz CJ, Kickuth R, Meffert RH, Wildenauer R, Lorenz U, Kellersmann R, Busch A. Clinical implications of fracture-associated vascular damage in extremity and pelvic trauma. BMC Musculoskelet Disord 2018; 19:404. [PMID: 30458745 PMCID: PMC6247697 DOI: 10.1186/s12891-018-2333-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/08/2018] [Accepted: 10/31/2018] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND Vascular damage in polytrauma patients is associated with high mortality and morbidity. Therefore, specific clinical implications of vascular damage with fractures in major trauma patients are reassessed. METHODS This comprehensive nine-year retrospective single center cohort study analyzed demography, laboratory, treatment and outcome data from 3689 patients, 64 patients with fracture-associated vascular injuries were identified and were compared to a control group. RESULTS Vascular damage occurred in 7% of patients with upper and lower limb and pelvic fractures admitted to the trauma room. Overall survival was 80% in pelvic fracture and 97% in extremity fracture patients and comparable to non-vascular trauma patients. Additional arterial damage required substantial fluid administration and was visible as significantly anemia and disturbed coagulation tests upon admission. Open procedures were done in over 80% of peripheral extremity vascular damage. Endovascular procedures were predominant (87%) in pelvic injury. CONCLUSION Vascular damage is associated with high mortality rates especially in combination with pelvic fractures. Initial anemia, disturbed coagulation tests and the need for extensive pre-clinical fluid substitution were observed in the cohort with vascular damage. Therefore, fast diagnosis and early interventional and surgical procedures are necessary to optimize patient-specific outcome.
Collapse
Affiliation(s)
- F. Gilbert
- Department of Orthopaedic Trauma, Hand, Plastic and Reconstructive Surgery, University Hospital Würzburg, Würzburg, Germany
- Department of Trauma Hand Plastic and Reconstructive Surgery, University Munich Germany, Julius-Maximilians-University of Würzburg Oberdürrbacherstr, 6 D-, 97080 Würzburg, Germany
| | - C. Schneemann
- Department for General Visceral, Vascular & Paediatric Surgery, University Hospital Würzburg, Würzburg, Germany
| | - C. J. Scholz
- Core Unit Systems Medicine IZKF, University Hospital Würzburg, Würzburg, Germany
| | - R. Kickuth
- Department of Diagnostic and Interventional Radiology, University Hospital Würzburg, Würzburg, Germany
| | - R. H. Meffert
- Department of Orthopaedic Trauma, Hand, Plastic and Reconstructive Surgery, University Hospital Würzburg, Würzburg, Germany
| | - R. Wildenauer
- Department for General Visceral, Vascular & Paediatric Surgery, University Hospital Würzburg, Würzburg, Germany
| | - U. Lorenz
- Department for General Visceral, Vascular & Paediatric Surgery, University Hospital Würzburg, Würzburg, Germany
| | - R. Kellersmann
- Department of Vascular Surgery, Klinikum Fulda, Fulda, Germany
| | - A. Busch
- Department for General Visceral, Vascular & Paediatric Surgery, University Hospital Würzburg, Würzburg, Germany
- Department for Vascular and Endovascular Surgery Klinikum rechts der Isar, Technical University Munich, Munich, Germany
| |
Collapse
|
15
|
Sturla Lompré J, Nievas M, Franco M, Grossi V, Ferrando A, Militon C, Gilbert F, Cuny P, Stora G, Sepúlveda M, Esteves J, Commendatore M. Fate of petroleum hydrocarbons in bioturbated pristine sediments from Caleta Valdés (Patagonia Argentina): An ex situ bioassay. Ecotoxicol Environ Saf 2018; 162:673-682. [PMID: 30025591 DOI: 10.1016/j.ecoenv.2018.06.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/12/2017] [Revised: 06/12/2018] [Accepted: 06/22/2018] [Indexed: 06/08/2023]
Abstract
Petroleum can pollute pristine shorelines as a consequence of accidental spills or chronic leaks. In this study, the fate of petroleum hydrocarbons in soft pristine sediment of Caleta Valdés (Argentina) subject to ex situ simulated oil pollution was assessed. Sedimentary columns were exposed to medium and high concentrations of Escalante Crude Oil (ECO) and incubated in the laboratory during 30 days. Levels of aliphatic hydrocarbons at different depths of the sedimentary column were determined by gas chromatography. Oil penetration was limited to the first three centimetres in both treatments, and under this depth, hydrocarbons were clearly biogenic (terrestrial plants) as in the whole sedimentary column of the control assay. Bioturbation by macrobenthic infauna was strongly impacted by oil pollution which resulted in reduced sediment oxygenation and low burial of petroleum hydrocarbons. This may partly explain the limited hydrocarbon biodegradation observed, as indicated by the relatively high values of the ratios nC17/pristane, nC18/phytane, and total resolved aliphatic hydrocarbons/unresolved complex mixture. Correspondingly, at the end of the experiment the most probable number of hydrocarbon-degrading bacteria reached ~ 103 MPN g-1 dry weight. These values were lower than those found in chronically polluted coastal sediments, reflecting a low activity level of the oil-degrading community. The results highlight the low attenuation capacities of Caleta Valdés pristine sediments to recover its original characteristics in a short time period if an oil spill occurs. In this work, we present a novel and integrative tool to evaluate the fate of petroleum hydrocarbons and their potential damage on pristine sediments.
Collapse
Affiliation(s)
- J Sturla Lompré
- Centro para el Estudio de Sistema Marinos, CONICET, Bvd. Brown 2915, Puerto Madryn 9120, Argentina.
| | - M Nievas
- Centro para el Estudio de Sistema Marinos, CONICET, Bvd. Brown 2915, Puerto Madryn 9120, Argentina; Universidad Tecnológica Nacional, Facultad Regional Chubut, Av. del Trabajo 1536, Puerto Madryn 9120, Argentina
| | - M Franco
- Universidad Tecnológica Nacional, Facultad Regional Chubut, Av. del Trabajo 1536, Puerto Madryn 9120, Argentina; Centro Nacional Patagónico, CONICET, Bvd. Brown 2915, Puerto Madryn 9120, Argentina
| | - V Grossi
- Laboratoire de Géologie de Lyon, Université Claude Bernard, Lyon 1, Campus Scientifique de la Doua, 69622 Villeurbanne, France
| | - A Ferrando
- Centro para el Estudio de Sistema Marinos, CONICET, Bvd. Brown 2915, Puerto Madryn 9120, Argentina; Universidad Tecnológica Nacional, Facultad Regional Chubut, Av. del Trabajo 1536, Puerto Madryn 9120, Argentina
| | - C Militon
- Aix-Marseille Université, CNRS, Université de Toulon, IRD, MIO UM 110, 13288 Marseille, France
| | - F Gilbert
- Laboratoire Ecologie Fonctionnelle et Environnement, Université de Toulouse, INP, UPS, 118 Route de Narbonne, 31062 Toulouse, France; CNRS, EcoLab, 31062 Toulouse, France
| | - P Cuny
- Aix-Marseille Université, CNRS, Université de Toulon, IRD, MIO UM 110, 13288 Marseille, France
| | - G Stora
- Aix-Marseille Université, CNRS, Université de Toulon, IRD, MIO UM 110, 13288 Marseille, France
| | - M Sepúlveda
- Centro para el Estudio de Sistema Marinos, CONICET, Bvd. Brown 2915, Puerto Madryn 9120, Argentina
| | - J Esteves
- Centro para el Estudio de Sistema Marinos, CONICET, Bvd. Brown 2915, Puerto Madryn 9120, Argentina
| | - M Commendatore
- Centro para el Estudio de Sistema Marinos, CONICET, Bvd. Brown 2915, Puerto Madryn 9120, Argentina
| |
Collapse
|
16
|
Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, Senkus E. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol 2018; 27:v103-v110. [PMID: 27664246 DOI: 10.1093/annonc/mdw327] [Citation(s) in RCA: 244] [Impact Index Per Article: 40.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Affiliation(s)
- S Paluch-Shimon
- Division of Oncology and the Dr Pinchas Borenstein Talpiot Medical Leadership Program, Sheba Medical Center, Ramat Gan, Israel
| | - F Cardoso
- Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal
| | - C Sessa
- Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland
| | - J Balmana
- Vall d`Hebron University Hospital Institut d'Oncologia, Barcelona, Spain
| | - M J Cardoso
- Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal
| | - F Gilbert
- School of Clinical Medicine, University of Cambridge, Cambridge, UK
| | - E Senkus
- Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland
| | | |
Collapse
|
17
|
Papalouka V, Kilburn-Toppin F, Gaskarth M, Gilbert F. MRI-guided breast biopsy: a review of technique, indications, and radiological-pathological correlations. Clin Radiol 2018; 73:908.e17-908.e25. [PMID: 30041954 DOI: 10.1016/j.crad.2018.05.029] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2017] [Accepted: 05/24/2018] [Indexed: 10/28/2022]
Abstract
Breast magnetic resonance imaging (MRI) is the technique of choice in detection, local staging, and monitoring of breast cancer; however, breast MRI results in the detection of more indeterminate/suspicious lesions that need to be histopathologically proven to guide patient management than any other breast imaging method. If such abnormalities are not detectable in any of the conventional imaging tools (mammography (MMG) or ultrasound) then an MRI-guided biopsy needs to be performed to obtain a diagnosis. Breast MRI-guided biopsy is a time-consuming and complex procedure that requires specific equipment and experienced, well-trained staff. This review article explores and illustrates the indications, the currently available technologies, and the technique of breast MRI-guided biopsy, and explains the importance of careful imaging review and selection of cases. We correlate the radiological-pathological findings and highlight the impact on patient management in a multidisciplinary setting.
Collapse
Affiliation(s)
- V Papalouka
- Department of Radiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0QQ, UK
| | - F Kilburn-Toppin
- Department of Radiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0QQ, UK.
| | - M Gaskarth
- Department of Radiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0QQ, UK
| | - F Gilbert
- Department of Radiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0QQ, UK
| |
Collapse
|
18
|
Gilbert F, Meffert RH, Schmalzl J, Weng AM, Köstler H, Eden L. Grade of retraction and tendon thickness correlates with MR-spectroscopically measured amount of fatty degeneration in full thickness supraspinatus tears. BMC Musculoskelet Disord 2018; 19:197. [PMID: 30037322 PMCID: PMC6055352 DOI: 10.1186/s12891-018-2096-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/12/2018] [Accepted: 05/16/2018] [Indexed: 12/11/2022] Open
Abstract
Background The amount of fatty degeneration (FD) has major impact on the clinical result and cuff integrity after rotator cuff repair. A quantitative analysis with magnet resonance imaging (MRI) spectroscopy was employed to analyze possible correlation of FD with tendon retraction, tendon thickness and patients’ characteristics in full thickness supraspinatus tears. Methods Forty-two patients with full-thickness supraspinatus tears underwent shoulder MRI including an experimental spectroscopic sequence allowing quantification of the fat fraction in the supraspinatus muscle belly. The amount of fatty degeneration was correlated with tendon retraction, tendon thickness, patients’ age, gender, smoker status, symptom duration and body mass index (BMI). Patients were divided in to three groups of retraction (A) 0-10 mm (n=), (B) 11-20 mm (n=) and (C) < 21 mm (n=) and the means of FD for each group were calculated. Results Tendon retraction (R = 0.6) and symptom duration (R = 0.6) correlated positively, whereas tendon thickness correlated negatively (R = − 0.6) with the amount of FD. The fat fraction increased significantly with tendon retraction: Group (A) showed a mean fat mount of 3.7% (±4%), group (B) of 16.7% (±8.2%) and group (C) of 37.5% (±19%). BMI, age and smoker-status only showed weak to moderate correlation with the amount of FD in this cohort. Conclusion MRI spectroscopy revealed significantly higher amount of fat with increasing grade of retraction, symptom duration and decreased tendon thickness. Thus, these parameters may indirectly be associated with the severity of tendon disease.
Collapse
Affiliation(s)
- F Gilbert
- Department of Trauma, Hand, Plastic and Reconstructive Surgery, Julius-Maximilians-University of Würzburg, Oberdürrbacherstr. 6, D-97080, Würzburg, Germany.
| | - R H Meffert
- Department of Trauma, Hand, Plastic and Reconstructive Surgery, Julius-Maximilians-University of Würzburg, Oberdürrbacherstr. 6, D-97080, Würzburg, Germany
| | - J Schmalzl
- Department of Traumatology and Hand Surgery, St. Vincentius Klinik, ViDia Kliniken, Suedendstraße 32, D-76137, Karlsruhe, Germany
| | - A M Weng
- Department of Radiology, Julius-Maximilians-University of Würzburg, Oberdürrbacherstr. 6, D-97080, Würzburg, Germany
| | - H Köstler
- Department of Radiology, Julius-Maximilians-University of Würzburg, Oberdürrbacherstr. 6, D-97080, Würzburg, Germany
| | - L Eden
- Department of Trauma, Hand, Plastic and Reconstructive Surgery, Julius-Maximilians-University of Würzburg, Oberdürrbacherstr. 6, D-97080, Würzburg, Germany
| |
Collapse
|
19
|
Zavidovique L, Gilbert F, Vercambre-Jacquot MN. Bien-être au travail et qualité de vie des enseignants : quelles différences selon l’ancienneté ? ARCH MAL PROF ENVIRO 2018. [DOI: 10.1016/j.admp.2017.09.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
20
|
Gilbert F, Eden L, Meffert R, Konietschke F, Lotz J, Bauer L, Staab W. Intra- and interobserver reliability of glenoid fracture classifications by Ideberg, Euler and AO. BMC Musculoskelet Disord 2018; 19:89. [PMID: 29580228 PMCID: PMC5870213 DOI: 10.1186/s12891-018-2016-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/03/2018] [Accepted: 03/21/2018] [Indexed: 01/24/2023] Open
Abstract
Background Representing 3%–5% of shoulder girdle injuries scapula fractures are rare. Furthermore, approximately 1% of scapula fractures are intraarticularfractures of the glenoid fossa. Because of uncertain fracture morphology and limited experience, the treatment of glenoid fossa fractures is difficult. The glenoid fracture classification by Ideberg (1984) and Euler (1996) is still commonly used in literature. In 2013 a new glenoid fracture classification was introduced by the AO. The purpose of this study was to examine the new AO classification in clinical practice in comparison with the classifications by Ideberg and Euler. Methods In total CT images of 84 patients with glenoid fossa fractures from 2005 to 2018 were included. Parasagittal, paracoronary and axial reconstructions were examined according to the classifications of Ideberg, Euler and the AO by 3 investigators (orthopedic surgeon, radiologist, student of medicine) at three individual time settings. Inter- and intraobserver reliability of the three classification systems were ascertained by computing Inter- and Intraclass (ICCs) correlation coefficients using Spearman’s rank correlation coefficient, 95%-confidence intervals as well as F-tests for correlation coefficients. Results Inter- and intraobserver reliability for the AO classification showed a perspicuous coherence (R = 0.74 and R = 0.79). Low to moderate intraobserver reliability for Ideberg (R = 0.46) and Euler classification (R = 0.41) was found. Furthermore, data show a low Interobserver reliability for both Ideberg and Euler classification (R < 0.2). Both the Inter- and Intraclass reliability using AO is significantly higher than those using Ideberg and Euler (p < 0.05). Using the new AO classification, it was possible to find a proper class for every glenoid fossa fracture. On average, according to Euler classification 10 of 84 fractures were not classifiable whereas to Ideberg classification 21 of 84 fractures were not classifiable. Conclusion The new AO classification system introduced 2013 facilitates reliable grading of glenoid fossa fractures with high inter- and intraobserver reliability in 84 patients using CT images. It should possibly be applied in order to enable a valid, reliable and consistent academic description of glenoid fossa fractures. The established classifications by Euler and Ideberg are not capable of providing a similar reliability.
Collapse
Affiliation(s)
- F Gilbert
- Department of Trauma, Hand, Plastic and Reconstructive Surgery, Julius-Maximilians-University of Würzburg, Würzburg, Germany.
| | - L Eden
- Department of Trauma, Hand, Plastic and Reconstructive Surgery, Julius-Maximilians-University of Würzburg, Würzburg, Germany
| | - R Meffert
- Department of Trauma, Hand, Plastic and Reconstructive Surgery, Julius-Maximilians-University of Würzburg, Würzburg, Germany
| | - F Konietschke
- Department of Mathematical Sciences, The University of Texas at Dallas, Richardson, TX, USA
| | - J Lotz
- Institute for Diagnostic and Interventional Radiology, University Medical Center Göttingen, Göttingen, Germany
| | - L Bauer
- Institute for Diagnostic and Interventional Radiology, University Medical Center Göttingen, Göttingen, Germany
| | - W Staab
- Institute for Diagnostic and Interventional Radiology, University Medical Center Göttingen, Göttingen, Germany
| |
Collapse
|
21
|
Gilbert F, Heintel TM, Jakubietz MG, Köstler H, Sebald C, Meffert RH, Weng AM. Quantitative MRI comparison of multifidus muscle degeneration in thoracolumbar fractures treated with open and minimally invasive approach. BMC Musculoskelet Disord 2018. [PMID: 29514622 PMCID: PMC5842610 DOI: 10.1186/s12891-018-2001-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Background Minimally invasive pedicle screw fixation has less approach-related morbidity than open screw placement and is allegedly less traumatizing on paravertebral muscles, as there is no requirement to mobilize and retract the adjacent muscle portion. The approach-related long-term effects to the morphology of the paravertebral muscles are unknown. The purpose of this study was to compare the long-term amount of fatty degeneration of the multifidus muscle in patients treated with a classical open or a minimally invasive approach. Methods Fourteen Patients meeting inclusion criteria were selected. In all patients a singular fracture of the thoracolumbar spine with a two-level posterior instrumentation was treated, either using an open approach or a minimally invasive approach. All patients underwent quantitative MRI spectroscopy for quantification of the fatty degeneration in the multifidus muscle as a long-term proof for muscle loss after minimum 4-year follow-up. Clinical outcome was assessed using Oswestry Low Back Pain Disability Questionnaire, SF-36 and VA-scale for pain. Results The minimally invasive approach group failed to show less muscle degeneration in comparison to the open group. Total amount of fatty degeneration was 14.22% in the MIS group and 12.60% in the open group (p = 0.64). In accordance to MRI quantitative results there was no difference in the clinical outcome after a mean follow up of 5.9 years (±1.8). Conclusion As short-term advantages of minimal invasive screw placement have been widely demonstrated, no advantage of the MIS, displaying a significant difference in the amount of fatty degeneration and resulting in a better clinical outcome could be found. Besides the well-known short-term advantage of minimally invasive pedicle screw placement, a long-term advantage, such as less muscle degeneration and thus superior clinical results, compared to the open approach could not be shown.
Collapse
Affiliation(s)
- F Gilbert
- Department of Trauma, Hand, Plastic and Reconstructive Surgery, Julius-Maximilians-University of Würzburg, Oberdürrbacherstr. 6, D-97080, Würzburg, Germany.
| | - T M Heintel
- Department of Trauma, Hand, Plastic and Reconstructive Surgery, Julius-Maximilians-University of Würzburg, Oberdürrbacherstr. 6, D-97080, Würzburg, Germany
| | - M G Jakubietz
- Department of Trauma, Hand, Plastic and Reconstructive Surgery, Julius-Maximilians-University of Würzburg, Oberdürrbacherstr. 6, D-97080, Würzburg, Germany
| | - H Köstler
- Department of Radiology Julius-Maximilians-University of Würzburg, Oberdürrbacherstr. 6, D-97080, Würzburg, Germany
| | - C Sebald
- Department of Trauma, Hand, Plastic and Reconstructive Surgery, Julius-Maximilians-University of Würzburg, Oberdürrbacherstr. 6, D-97080, Würzburg, Germany
| | - R H Meffert
- Department of Trauma, Hand, Plastic and Reconstructive Surgery, Julius-Maximilians-University of Würzburg, Oberdürrbacherstr. 6, D-97080, Würzburg, Germany
| | - A M Weng
- Department of Radiology Julius-Maximilians-University of Würzburg, Oberdürrbacherstr. 6, D-97080, Würzburg, Germany
| |
Collapse
|
22
|
Vercambre-Jacquot MN, Gilbert F, Billaudeau N. [Teacher sick leave: Prevalence, duration, reasons and covariates]. Rev Epidemiol Sante Publique 2017; 66:19-31. [PMID: 29290454 DOI: 10.1016/j.respe.2017.10.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Revised: 08/03/2017] [Accepted: 10/20/2017] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND Absences from work have considerable social and economic impact. In the education sector, the phenomenon is particularly worrying since teacher sick leave has an impact on the overall performance of the education system. Yet, available data are scarce. METHODS In April-June 2013, 2653 teachers responded to a population-based postal survey on their quality of life (enquête Qualité de vie des enseignants, MGEN Foundation/Ministry of education, response rate 53 %). Besides questions on work environment and health, teachers were asked to describe their eventual sick leave(s) since the beginning of the school year: duration, type and medical reasons. Self-reported information was reinforced by administrative data from ministerial databases and weighted to be extrapolated to all French teachers. Tobit models adjusted for individual factors of a private nature were used to investigate different occupational risk factors of teacher sick leave, taking into account both the estimated effect on the probability of sick leave and the length of it. RESULTS More than one in three teachers (36 %) reported having had at least one day of sick leave since the beginning of the school year. Respiratory/ENT diseases were the leading reason for sick leave (37 %). However, and because sick leave duration depended on the underlying health problem, such diseases came in third place among justifications of sick leave days (14 %), far behind musculoskeletal problems (27 %) and neurological and psychological disorders (25 %). Tobit models suggested that some occupational factors significantly associated with the risk of sick leave may represent promising preventive targets, including high psychological demand, workplace violence and unfavorable socio-environmental context. CONCLUSION Our study provides objective evidence about the issue of sick leave among French teachers, highlighting the usefulness of implementing actions to minimize its weight. To this end, the study findings point-out the importance of considering not only the probability of sick leave, but also its duration.
Collapse
Affiliation(s)
- M-N Vercambre-Jacquot
- Fondation d'entreprise MGEN pour la santé publique, 3, square Max-Hymans, 75748 Paris cedex 15, France.
| | - F Gilbert
- Fondation d'entreprise MGEN pour la santé publique, 3, square Max-Hymans, 75748 Paris cedex 15, France
| | - N Billaudeau
- Fondation d'entreprise MGEN pour la santé publique, 3, square Max-Hymans, 75748 Paris cedex 15, France
| |
Collapse
|
23
|
Baird RD, Ramenatte N, Watts C, Jonson A, Jones L, Biggs H, Harrison E, Oberg I, Bullen G, Williams M, Qian W, Gilbert F, Jodrell D, Caldas C, Karabatsou K, Dunn L, Jena R, Whitfield G, Chalmers A, Jefferies S, Price S. Abstract OT1-04-01: Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot1-04-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Failure of drugs to cross the blood brain barrier (BBB) can be a major reason for treatment failure for patients with brain tumors. For most patients who don't respond to treatment, it is not known whether this is due to inadequate drug concentrations in the tumor, or due to drug resistance. Preliminary data suggest that low-dose radiotherapy may disrupt the BBB, and could facilitate increased drug delivery into brain tumors. Afatinib is a potent, irreversible inhibitor of EGFR / HER2 / HER4 and takes approximately 8 days to achieve steady-state concentrations in cancer patients.
Aims
CamBMT1 has been designed to investigate the delivery of afatinib into brain metastases and whether this might be enhanced by low dose-radiotherapy.
Patient Population
Key eligibility criteria
Patients with operable brain metastases from breast or lung primaries for whom neurosurgical resection would be standard of care, as determined by the local multi-disciplinary team. ECOG PS 0, 1 or 2.
Trial design
After a phase 1b safety run- in, the phase 2 part of the trial randomises patients (n=60) into 3 pre-operative arms:
Arm 1afatinib alone for 11 days, then neurosurgery on day 12Arm 2afatinib for 11 days plus a single 2 Gy fraction on day 10, then neurosurgery on day 12Arm 3afatinib for 11 days plus a single 4 Gy fraction on day 10, then neurosurgery on day 12
Primary endpoint: to compare steady-state afatinib concentration in resected brain metastases, following afatinib administered alone, or in combination with radiotherapy (2 Gy or 4 Gy). Afatinib concentrations are measured in the resected brain metastases and in plasma.
Secondary endpoints: safety of afatinib administration in combination with radiotherapy; and multi-sequence MRI (optional) to detect changes in perfusion, vascular density, blood-brain-barrier permeability and interstitial pressure.
Exploratory endpoints: molecular profiling of resected brain metastases, for comparison with paired primary lung and breast cancers; the establishment and study of patient-derived xenografts.
Statistical methods
With 20 patients randomised in each of 3 arms in the phase 2 part of CamBMT1, the trial has a power of 84% at a significance level of 20% (one-sided) to detect an increase in afatinib concentrations with targeted radiotherapy, measured as a Cohen's D (standardised mean difference) ≥0.5.
Accrual
By the end of q2 2016, phase 1b had nearly completed enrolment. The randomised phase 2 part of CamBMT1 is due to open by q4 2016 at additional Experimental Cancer Medicine Centres.
Acknowledgments
CamBMT1 is funded by Cancer Research UK, the Brain Tumour Charity and Boehringer-Ingelheim.
Citation Format: Baird RD, Ramenatte N, Watts C, Jonson A, Jones L, Biggs H, Harrison E, Oberg I, Bullen G, Williams M, Qian W, Gilbert F, Jodrell D, Caldas C, Karabatsou K, Dunn L, Jena R, Whitfield G, Chalmers A, Jefferies S, Price S. Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT1-04-01.
Collapse
Affiliation(s)
- RD Baird
- Cambridge Cancer Centre - Breast Cancer Research Unit, Cambridge, Cambridgeshire, United Kingdom; Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, Cambridgeshire, United Kingdom; Cambridge Cancer Centre - Early Phase Clinical Trials Team, Cambridge, Cambridgeshire, United Kingdom; University of Cambridge, Cambridge, Cambridgeshire, United Kingdom; Neuro-Oncology, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom; Cancer Research UK Cambridge Institute - PK-PD Core Facility, Cambridge, Cambridgeshire, United Kingdom; University of Glasgow - Neuro-Oncology, Glasgow, United Kingdom; University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom; University of Cambridge - Cambridge Cancer Centre, United Kingdom
| | - N Ramenatte
- Cambridge Cancer Centre - Breast Cancer Research Unit, Cambridge, Cambridgeshire, United Kingdom; Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, Cambridgeshire, United Kingdom; Cambridge Cancer Centre - Early Phase Clinical Trials Team, Cambridge, Cambridgeshire, United Kingdom; University of Cambridge, Cambridge, Cambridgeshire, United Kingdom; Neuro-Oncology, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom; Cancer Research UK Cambridge Institute - PK-PD Core Facility, Cambridge, Cambridgeshire, United Kingdom; University of Glasgow - Neuro-Oncology, Glasgow, United Kingdom; University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom; University of Cambridge - Cambridge Cancer Centre, United Kingdom
| | - C Watts
- Cambridge Cancer Centre - Breast Cancer Research Unit, Cambridge, Cambridgeshire, United Kingdom; Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, Cambridgeshire, United Kingdom; Cambridge Cancer Centre - Early Phase Clinical Trials Team, Cambridge, Cambridgeshire, United Kingdom; University of Cambridge, Cambridge, Cambridgeshire, United Kingdom; Neuro-Oncology, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom; Cancer Research UK Cambridge Institute - PK-PD Core Facility, Cambridge, Cambridgeshire, United Kingdom; University of Glasgow - Neuro-Oncology, Glasgow, United Kingdom; University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom; University of Cambridge - Cambridge Cancer Centre, United Kingdom
| | - A Jonson
- Cambridge Cancer Centre - Breast Cancer Research Unit, Cambridge, Cambridgeshire, United Kingdom; Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, Cambridgeshire, United Kingdom; Cambridge Cancer Centre - Early Phase Clinical Trials Team, Cambridge, Cambridgeshire, United Kingdom; University of Cambridge, Cambridge, Cambridgeshire, United Kingdom; Neuro-Oncology, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom; Cancer Research UK Cambridge Institute - PK-PD Core Facility, Cambridge, Cambridgeshire, United Kingdom; University of Glasgow - Neuro-Oncology, Glasgow, United Kingdom; University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom; University of Cambridge - Cambridge Cancer Centre, United Kingdom
| | - L Jones
- Cambridge Cancer Centre - Breast Cancer Research Unit, Cambridge, Cambridgeshire, United Kingdom; Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, Cambridgeshire, United Kingdom; Cambridge Cancer Centre - Early Phase Clinical Trials Team, Cambridge, Cambridgeshire, United Kingdom; University of Cambridge, Cambridge, Cambridgeshire, United Kingdom; Neuro-Oncology, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom; Cancer Research UK Cambridge Institute - PK-PD Core Facility, Cambridge, Cambridgeshire, United Kingdom; University of Glasgow - Neuro-Oncology, Glasgow, United Kingdom; University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom; University of Cambridge - Cambridge Cancer Centre, United Kingdom
| | - H Biggs
- Cambridge Cancer Centre - Breast Cancer Research Unit, Cambridge, Cambridgeshire, United Kingdom; Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, Cambridgeshire, United Kingdom; Cambridge Cancer Centre - Early Phase Clinical Trials Team, Cambridge, Cambridgeshire, United Kingdom; University of Cambridge, Cambridge, Cambridgeshire, United Kingdom; Neuro-Oncology, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom; Cancer Research UK Cambridge Institute - PK-PD Core Facility, Cambridge, Cambridgeshire, United Kingdom; University of Glasgow - Neuro-Oncology, Glasgow, United Kingdom; University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom; University of Cambridge - Cambridge Cancer Centre, United Kingdom
| | - E Harrison
- Cambridge Cancer Centre - Breast Cancer Research Unit, Cambridge, Cambridgeshire, United Kingdom; Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, Cambridgeshire, United Kingdom; Cambridge Cancer Centre - Early Phase Clinical Trials Team, Cambridge, Cambridgeshire, United Kingdom; University of Cambridge, Cambridge, Cambridgeshire, United Kingdom; Neuro-Oncology, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom; Cancer Research UK Cambridge Institute - PK-PD Core Facility, Cambridge, Cambridgeshire, United Kingdom; University of Glasgow - Neuro-Oncology, Glasgow, United Kingdom; University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom; University of Cambridge - Cambridge Cancer Centre, United Kingdom
| | - I Oberg
- Cambridge Cancer Centre - Breast Cancer Research Unit, Cambridge, Cambridgeshire, United Kingdom; Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, Cambridgeshire, United Kingdom; Cambridge Cancer Centre - Early Phase Clinical Trials Team, Cambridge, Cambridgeshire, United Kingdom; University of Cambridge, Cambridge, Cambridgeshire, United Kingdom; Neuro-Oncology, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom; Cancer Research UK Cambridge Institute - PK-PD Core Facility, Cambridge, Cambridgeshire, United Kingdom; University of Glasgow - Neuro-Oncology, Glasgow, United Kingdom; University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom; University of Cambridge - Cambridge Cancer Centre, United Kingdom
| | - G Bullen
- Cambridge Cancer Centre - Breast Cancer Research Unit, Cambridge, Cambridgeshire, United Kingdom; Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, Cambridgeshire, United Kingdom; Cambridge Cancer Centre - Early Phase Clinical Trials Team, Cambridge, Cambridgeshire, United Kingdom; University of Cambridge, Cambridge, Cambridgeshire, United Kingdom; Neuro-Oncology, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom; Cancer Research UK Cambridge Institute - PK-PD Core Facility, Cambridge, Cambridgeshire, United Kingdom; University of Glasgow - Neuro-Oncology, Glasgow, United Kingdom; University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom; University of Cambridge - Cambridge Cancer Centre, United Kingdom
| | - M Williams
- Cambridge Cancer Centre - Breast Cancer Research Unit, Cambridge, Cambridgeshire, United Kingdom; Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, Cambridgeshire, United Kingdom; Cambridge Cancer Centre - Early Phase Clinical Trials Team, Cambridge, Cambridgeshire, United Kingdom; University of Cambridge, Cambridge, Cambridgeshire, United Kingdom; Neuro-Oncology, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom; Cancer Research UK Cambridge Institute - PK-PD Core Facility, Cambridge, Cambridgeshire, United Kingdom; University of Glasgow - Neuro-Oncology, Glasgow, United Kingdom; University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom; University of Cambridge - Cambridge Cancer Centre, United Kingdom
| | - W Qian
- Cambridge Cancer Centre - Breast Cancer Research Unit, Cambridge, Cambridgeshire, United Kingdom; Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, Cambridgeshire, United Kingdom; Cambridge Cancer Centre - Early Phase Clinical Trials Team, Cambridge, Cambridgeshire, United Kingdom; University of Cambridge, Cambridge, Cambridgeshire, United Kingdom; Neuro-Oncology, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom; Cancer Research UK Cambridge Institute - PK-PD Core Facility, Cambridge, Cambridgeshire, United Kingdom; University of Glasgow - Neuro-Oncology, Glasgow, United Kingdom; University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom; University of Cambridge - Cambridge Cancer Centre, United Kingdom
| | - F Gilbert
- Cambridge Cancer Centre - Breast Cancer Research Unit, Cambridge, Cambridgeshire, United Kingdom; Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, Cambridgeshire, United Kingdom; Cambridge Cancer Centre - Early Phase Clinical Trials Team, Cambridge, Cambridgeshire, United Kingdom; University of Cambridge, Cambridge, Cambridgeshire, United Kingdom; Neuro-Oncology, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom; Cancer Research UK Cambridge Institute - PK-PD Core Facility, Cambridge, Cambridgeshire, United Kingdom; University of Glasgow - Neuro-Oncology, Glasgow, United Kingdom; University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom; University of Cambridge - Cambridge Cancer Centre, United Kingdom
| | - D Jodrell
- Cambridge Cancer Centre - Breast Cancer Research Unit, Cambridge, Cambridgeshire, United Kingdom; Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, Cambridgeshire, United Kingdom; Cambridge Cancer Centre - Early Phase Clinical Trials Team, Cambridge, Cambridgeshire, United Kingdom; University of Cambridge, Cambridge, Cambridgeshire, United Kingdom; Neuro-Oncology, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom; Cancer Research UK Cambridge Institute - PK-PD Core Facility, Cambridge, Cambridgeshire, United Kingdom; University of Glasgow - Neuro-Oncology, Glasgow, United Kingdom; University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom; University of Cambridge - Cambridge Cancer Centre, United Kingdom
| | - C Caldas
- Cambridge Cancer Centre - Breast Cancer Research Unit, Cambridge, Cambridgeshire, United Kingdom; Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, Cambridgeshire, United Kingdom; Cambridge Cancer Centre - Early Phase Clinical Trials Team, Cambridge, Cambridgeshire, United Kingdom; University of Cambridge, Cambridge, Cambridgeshire, United Kingdom; Neuro-Oncology, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom; Cancer Research UK Cambridge Institute - PK-PD Core Facility, Cambridge, Cambridgeshire, United Kingdom; University of Glasgow - Neuro-Oncology, Glasgow, United Kingdom; University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom; University of Cambridge - Cambridge Cancer Centre, United Kingdom
| | - K Karabatsou
- Cambridge Cancer Centre - Breast Cancer Research Unit, Cambridge, Cambridgeshire, United Kingdom; Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, Cambridgeshire, United Kingdom; Cambridge Cancer Centre - Early Phase Clinical Trials Team, Cambridge, Cambridgeshire, United Kingdom; University of Cambridge, Cambridge, Cambridgeshire, United Kingdom; Neuro-Oncology, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom; Cancer Research UK Cambridge Institute - PK-PD Core Facility, Cambridge, Cambridgeshire, United Kingdom; University of Glasgow - Neuro-Oncology, Glasgow, United Kingdom; University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom; University of Cambridge - Cambridge Cancer Centre, United Kingdom
| | - L Dunn
- Cambridge Cancer Centre - Breast Cancer Research Unit, Cambridge, Cambridgeshire, United Kingdom; Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, Cambridgeshire, United Kingdom; Cambridge Cancer Centre - Early Phase Clinical Trials Team, Cambridge, Cambridgeshire, United Kingdom; University of Cambridge, Cambridge, Cambridgeshire, United Kingdom; Neuro-Oncology, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom; Cancer Research UK Cambridge Institute - PK-PD Core Facility, Cambridge, Cambridgeshire, United Kingdom; University of Glasgow - Neuro-Oncology, Glasgow, United Kingdom; University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom; University of Cambridge - Cambridge Cancer Centre, United Kingdom
| | - R Jena
- Cambridge Cancer Centre - Breast Cancer Research Unit, Cambridge, Cambridgeshire, United Kingdom; Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, Cambridgeshire, United Kingdom; Cambridge Cancer Centre - Early Phase Clinical Trials Team, Cambridge, Cambridgeshire, United Kingdom; University of Cambridge, Cambridge, Cambridgeshire, United Kingdom; Neuro-Oncology, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom; Cancer Research UK Cambridge Institute - PK-PD Core Facility, Cambridge, Cambridgeshire, United Kingdom; University of Glasgow - Neuro-Oncology, Glasgow, United Kingdom; University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom; University of Cambridge - Cambridge Cancer Centre, United Kingdom
| | - G Whitfield
- Cambridge Cancer Centre - Breast Cancer Research Unit, Cambridge, Cambridgeshire, United Kingdom; Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, Cambridgeshire, United Kingdom; Cambridge Cancer Centre - Early Phase Clinical Trials Team, Cambridge, Cambridgeshire, United Kingdom; University of Cambridge, Cambridge, Cambridgeshire, United Kingdom; Neuro-Oncology, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom; Cancer Research UK Cambridge Institute - PK-PD Core Facility, Cambridge, Cambridgeshire, United Kingdom; University of Glasgow - Neuro-Oncology, Glasgow, United Kingdom; University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom; University of Cambridge - Cambridge Cancer Centre, United Kingdom
| | - A Chalmers
- Cambridge Cancer Centre - Breast Cancer Research Unit, Cambridge, Cambridgeshire, United Kingdom; Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, Cambridgeshire, United Kingdom; Cambridge Cancer Centre - Early Phase Clinical Trials Team, Cambridge, Cambridgeshire, United Kingdom; University of Cambridge, Cambridge, Cambridgeshire, United Kingdom; Neuro-Oncology, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom; Cancer Research UK Cambridge Institute - PK-PD Core Facility, Cambridge, Cambridgeshire, United Kingdom; University of Glasgow - Neuro-Oncology, Glasgow, United Kingdom; University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom; University of Cambridge - Cambridge Cancer Centre, United Kingdom
| | - S Jefferies
- Cambridge Cancer Centre - Breast Cancer Research Unit, Cambridge, Cambridgeshire, United Kingdom; Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, Cambridgeshire, United Kingdom; Cambridge Cancer Centre - Early Phase Clinical Trials Team, Cambridge, Cambridgeshire, United Kingdom; University of Cambridge, Cambridge, Cambridgeshire, United Kingdom; Neuro-Oncology, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom; Cancer Research UK Cambridge Institute - PK-PD Core Facility, Cambridge, Cambridgeshire, United Kingdom; University of Glasgow - Neuro-Oncology, Glasgow, United Kingdom; University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom; University of Cambridge - Cambridge Cancer Centre, United Kingdom
| | - S Price
- Cambridge Cancer Centre - Breast Cancer Research Unit, Cambridge, Cambridgeshire, United Kingdom; Cambridge Clinical Trials Unit – Cancer Theme, Cambridge, Cambridgeshire, United Kingdom; Cambridge Cancer Centre - Early Phase Clinical Trials Team, Cambridge, Cambridgeshire, United Kingdom; University of Cambridge, Cambridge, Cambridgeshire, United Kingdom; Neuro-Oncology, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom; Cancer Research UK Cambridge Institute - PK-PD Core Facility, Cambridge, Cambridgeshire, United Kingdom; University of Glasgow - Neuro-Oncology, Glasgow, United Kingdom; University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom; University of Cambridge - Cambridge Cancer Centre, United Kingdom
| |
Collapse
|
24
|
Caetano G, Gilbert F, Loie C, Lapie-Legouis P, Garsi JP. Trouble vocal chez les enseignants : vers une prévention collective ? ARCH MAL PROF ENVIRO 2016. [DOI: 10.1016/j.admp.2016.10.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
25
|
de Clercq D, Sacko M, Behnke J, Gilbert F, Vercruysse J. The relationship between Schistosoma haematobium infection and school performance and attendance in Bamako, Mali. Annals of Tropical Medicine & Parasitology 2016. [DOI: 10.1080/00034983.1998.11813350] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
26
|
Donnelly Y, Brennan S, Gilbert F, Gorham A, Parks C, Glynn A. MON-P088: Establishing a Reactive Homeng Service Using Cortrak Enteral Access System (EAS) for Head and Neck Cancer Patients Undergoing Radiotherapy and/or Chemotherapy. Clin Nutr 2016. [DOI: 10.1016/s0261-5614(16)30722-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
27
|
Vercambre-Jacquot MN, Gilbert F. Bien-être professionnel et qualité de vie des enseignants : quelles évolutions sur 15ans ? Rev Epidemiol Sante Publique 2016. [DOI: 10.1016/j.respe.2016.06.285] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
28
|
Smith R, Bryan M, Campbell K, Cooney L, Gilbert F, Hamill T, Scott A, Williams K. The challenges of an autologous cell therapy product in clinical trials. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61480-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
29
|
Mohamed NE, Gilbert F, Lee CT, Sfakianos J, Knauer C, Mehrazin R, Badr H, Wittmann D, Downs T, Berry D, Given B, Wiklund P, Steineck G. Pursuing Quality in the Application of Bladder Cancer Quality of Life Research. Bladder Cancer 2016; 2:139-149. [PMID: 27376136 PMCID: PMC4927895 DOI: 10.3233/blc-160051] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Patient-reported outcomes (PRO), including health-related quality of life (HRQOL) measures, represent important means for evaluating patients' health outcomes and for guiding health care decisions made by patients, practitioners, investigators, and policy makers. In spite of the large number of studies examining HRQOL in patients with bladder cancer, very few review articles investigated this topic. Because these review studies report mixed results, incorporating bladder cancer HRQOL measures into standard urological practice is not a viable option. In this non-systematic review of the literature and commentary we note some general concerns regarding PRO research, but our primary focus is on the HRQOL methodology within the context of two types of bladder cancer: muscle invasive and non-muscle invasive bladder cancer. Considering bladder cancer HRQOL as the interaction of four areas of the assessment process (i.e., what model of HRQOL to choose, what instruments are available to fit the choice, how interpretation of the resulting data fits the model, and how to derive some utility from the chosen model) and the two types of disease (i.e., muscle invasive and non-muscle invasive) may move us toward a better understanding of bladder cancer HRQOL. Establishing a useful model of perceived general health or specific symptoms is the first and most important step in developing the responsive bladder cancer HRQOL measures necessitated by clinical settings.
Collapse
Affiliation(s)
- N E Mohamed
- Department of Urology, Icahn School of Medicine at Mount Sinai , New York, NY, USA
| | | | - C T Lee
- Department of Urology, University of Michigan , Ann Arbor, MI, USA
| | - J Sfakianos
- Department of Urology, Icahn School of Medicine at Mount Sinai , New York, NY, USA
| | - C Knauer
- Department of Urology, Icahn School of Medicine at Mount Sinai , New York, NY, USA
| | - R Mehrazin
- Department of Urology, Icahn School of Medicine at Mount Sinai , New York, NY, USA
| | - H Badr
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai , New York, NY, USA
| | | | - T Downs
- Department of Urology, University of Wisconsin , Madison, WI, USA
| | - D Berry
- Dana-Farber Cancer Institute , Boston, MA, USA
| | - B Given
- Department of Medicine, Harvard Medical School, Dana-Farber Cancer Institute , Boston, MA, USA
| | - P Wiklund
- Department of Urology, Icahn School of Medicine at Mount Sinai , New York, NY, USA
| | - G Steineck
- Division of Clinical Cancer Epidemiology, Sahlgrenska universitetssjukhuset , Göteborg, Sweden
| |
Collapse
|
30
|
Billaudeau N, Gilbert F, Lapie-Legouis P, Vercambre-Jacquot M. Enquête « Qualité de vie des enseignants » : état des lieux. ARCH MAL PROF ENVIRO 2015. [DOI: 10.1016/j.admp.2015.04.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
31
|
Sieker JT, Kunz M, Weißenberger M, Gilbert F, Frey S, Rudert M, Steinert AF. Direct bone morphogenetic protein 2 and Indian hedgehog gene transfer for articular cartilage repair using bone marrow coagulates. Osteoarthritis Cartilage 2015; 23:433-42. [PMID: 25463442 DOI: 10.1016/j.joca.2014.11.008] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/20/2014] [Revised: 11/01/2014] [Accepted: 11/05/2014] [Indexed: 02/02/2023]
Abstract
OBJECTIVE Bone morphogenetic protein 2 (BMP-2, encoded by BMP2) and Indian hedgehog protein (IHH, encoded by IHH) are well known regulators of chondrogenesis and chondrogenic hypertrophy. Despite being a potent chondrogenic factor BMP-2 was observed to induce chondrocyte hypertrophy in osteoarthritis (OA), growth plate cartilage and adult mesenchymal stem cells (MSCs). IHH might induce chondrogenic differentiation through different intracellular signalling pathways without inducing subsequent chondrocyte hypertrophy. The primary objective of this study is to test the efficacy of direct BMP2 and IHH gene delivery via bone marrow coagulates to influence histological repair cartilage quality in vivo. METHOD Vector-laden autologous bone marrow coagulates with 10(11) adenoviral vector particles encoding BMP2, IHH or the Green fluorescent protein (GFP) were delivered to 3.2 mm osteochondral defects in the trochlea of rabbit knees. After 13 weeks the histological repair cartilage quality was assessed using the ICRS II scoring system and the type II collagen positive area. RESULTS IHH treatment resulted in superior histological repair cartilage quality than GFP controls in all of the assessed parameters (with P < 0.05 in five of 14 assessed parameters). Results of BMP2 treatment varied substantially, including severe intralesional bone formation in two of six joints after 13 weeks. CONCLUSION IHH gene transfer is effective to improve repair cartilage quality in vivo, whereas BMP2 treatment, carried the risk intralesional bone formation. Therefore IHH protein can be considered as an attractive alternative candidate growth factor for further preclinical research and development towards improved treatments for articular cartilage defects.
Collapse
Affiliation(s)
- J T Sieker
- Department of Orthopaedic Surgery, König-Ludwig-Haus, Julius-Maximilians-University of Würzburg, Germany.
| | - M Kunz
- Department of Orthopaedic Surgery, König-Ludwig-Haus, Julius-Maximilians-University of Würzburg, Germany.
| | - M Weißenberger
- Department of Orthopaedic Surgery, König-Ludwig-Haus, Julius-Maximilians-University of Würzburg, Germany.
| | - F Gilbert
- Department of Orthopaedic Surgery, König-Ludwig-Haus, Julius-Maximilians-University of Würzburg, Germany; Department of Trauma, Hand, Plastic and Reconstructive Surgery, Julius-Maximilians-University of Würzburg, Germany.
| | - S Frey
- Department of Trauma, Hand, Plastic and Reconstructive Surgery, Julius-Maximilians-University of Würzburg, Germany.
| | - M Rudert
- Department of Orthopaedic Surgery, König-Ludwig-Haus, Julius-Maximilians-University of Würzburg, Germany.
| | - A F Steinert
- Department of Orthopaedic Surgery, König-Ludwig-Haus, Julius-Maximilians-University of Würzburg, Germany.
| |
Collapse
|
32
|
Lejeune F, Parmentier F, Gilbert F, Neri C. B02 Systems Modelling And Network-based Approaches For Basic And Translational Research In Huntington's Disease. Journal of Neurology, Neurosurgery & Psychiatry 2014. [DOI: 10.1136/jnnp-2014-309032.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
33
|
Gendreau J, Gilbert F, Lapie-Legouis P, Sevilla-Dedieu C. Recours au médecin endocrinologue dans une population diabétique (France). Rev Epidemiol Sante Publique 2014. [DOI: 10.1016/j.respe.2014.06.050] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
34
|
Gendreau J, Gilbert F, Lapie-Legouis P, Sevilla-Dedieu C. Qualité du suivi médical des diabétiques de la Mutuelle générale de l’éducation nationale (France). Rev Epidemiol Sante Publique 2014. [DOI: 10.1016/j.respe.2014.06.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
35
|
Sadeghi H, Rotheray G, Laska P, Gilbert F. Host preferences of aphidophagous hoverflies from field distribution of their larvae. ACTA ACUST UNITED AC 2014. [DOI: 10.4314/ejb.v16i1.1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
36
|
Green PR, Gentle L, Peake TM, Scudamore RE, McGregor PK, Gilbert F, Dittrich WH. Conditioning pigeons to discriminate naturally lit insect specimens. Behav Processes 2014; 46:97-102. [PMID: 24925502 DOI: 10.1016/s0376-6357(99)00022-4] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/1998] [Revised: 02/09/1999] [Accepted: 02/12/1999] [Indexed: 10/17/2022]
Abstract
Pigeons (Columba livia) were trained on a visual discrimination task using a novel apparatus which enabled pinned specimens of insects, illuminated by natural daylight, to be presented under a pecking key transparent to ultraviolet light. Three birds showed evidence of learning to discriminate between sets of wasp and fly specimens. This response transferred to specimens of four hoverfly species, the strength of the response varying between the different hoverfly species. This conditioning technique offers a promising means of analysing mechanisms of visual processing in birds that are relevant to theories of the evolution of camouflage and mimicry.
Collapse
Affiliation(s)
- P R Green
- Department of Psychology, University of Nottingham, Nottingham NG7 2RD, UK.
| | - L Gentle
- Department of Life Science, University of Nottingham, Nottingham NG7 2RD, UK
| | - T M Peake
- Department of Life Science, University of Nottingham, Nottingham NG7 2RD, UK
| | - R E Scudamore
- Department of Life Science, University of Nottingham, Nottingham NG7 2RD, UK
| | - P K McGregor
- Department of Life Science, University of Nottingham, Nottingham NG7 2RD, UK
| | - F Gilbert
- Department of Life Science, University of Nottingham, Nottingham NG7 2RD, UK
| | - W H Dittrich
- Department of Psychology, University of Exeter, Exeter EX4 4QG, UK
| |
Collapse
|
37
|
Tromans C, Highnam R, Morrish O, Black R, Tucker L, Gilbert F, Brady M. TU-F-18C-06: Which Women Based On Clinical Benefits and Dose Should Be Considered For Breast Screening with Tomosynthesis? Med Phys 2014. [DOI: 10.1118/1.4889351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
38
|
Wilson A, Cameron D, Evans G, Broeders M, Lerda D, Knox S, Gilbert F, Skaane P, Evans A, Mann R, Bick U, Ramirez A, Michell M. E03. Update on breast cancer screening. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70055-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
39
|
Poulalhon C, Gilbert F, Cecchi-Tenerini R, Lapie-Legouis P, Sevilla-Dedieu C. Dépistage du cancer du col chez les femmes de la Mutuelle générale de l’éducation nationale, France. Rev Epidemiol Sante Publique 2013. [DOI: 10.1016/j.respe.2013.07.250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
40
|
Mermillod-Blondin F, Foulquier A, Gilbert F, Navel S, Montuelle B, Bellvert F, Comte G, Grossi V, Fourel F, Lecuyer C, Simon L. Benzo(a)pyrene inhibits the role of the bioturbator Tubifex tubifex in river sediment biogeochemistry. Sci Total Environ 2013; 450-451:230-241. [PMID: 23500821 DOI: 10.1016/j.scitotenv.2013.02.013] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/01/2012] [Revised: 02/06/2013] [Accepted: 02/08/2013] [Indexed: 06/01/2023]
Abstract
The interactions between invertebrates and micro-organisms living in streambed sediments often play key roles in the regulation of nutrient and organic matter fluxes in aquatic ecosystems. However, benthic sediments also constitute a privileged compartment for the accumulation of persistent organic pollutants such as PAHs or PCBs that may affect the diversity, abundance and activity of benthic organisms. The objective of this study was to quantify the impact of sediment contamination with the PAH benzo(a)pyrene on the interaction between micro-organisms and the tubificid worm, Tubifex tubifex, which has been recognized as a major bioturbator in freshwater sediments. Sedimentary microcosms (slow filtration columns) contaminated or not with benzo(a)pyrene (3 tested concentrations: 0, 1 and 5 mg kg(-1)) at the sediment surface were incubated under laboratory conditions in the presence (100 individuals) or absence of T. tubifex. Although the surface sediment contaminations with 1 mg kg(-1) and 5 mg kg(-1) of benzo(a)pyrene did not affect tubificid worm survival, these contaminations significantly influenced the role played by T. tubifex in biogeochemical processes. Indeed, tubificid worms stimulated aerobic respiration, denitrification, dehydrogenase and hydrolytic activities of micro-organisms in uncontaminated sediments whereas such effects were inhibited in sediments polluted with benzo(a)pyrene. This inhibition was due to contaminant-induced changes in bioturbation (and especially bio-irrigation) activities of worms and their resulting effects on microbial processes. This study reveals the importance of sublethal concentrations of a contaminant on ecological processes in river sediments through affecting bioturbator-microbe interactions. Since they affect microbial processes involved in water purification processes, such impacts of sublethal concentrations of pollutants should be more often considered in ecosystem health assessment.
Collapse
Affiliation(s)
- F Mermillod-Blondin
- Université de Lyon, UMR5023 Ecologie des Hydrosystèmes Naturels et Anthropisés, Université Lyon 1, ENTPE, CNRS, 6 rue Raphaël Dubois, 69622 Villeurbanne, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
|
42
|
Connor SJ, Lim YY, Tate C, Entwistle H, Morris J, Whiteside S, Sergeant J, Wilson M, Beetles U, Boggis C, Gilbert F, Astley S. A comparison of reading times in full-field digital mammography and digital breast tomosynthesis. Breast Cancer Res 2012. [PMCID: PMC3542700 DOI: 10.1186/bcr3281] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
43
|
Cosker K, Sevilla-Dedieu C, Gilbert F, Lapie-Legouis P, Cecchi-Tenerini R. Suivi médical du diabète chez les assurés de la Mutuelle générale de l’éducation nationale, France. Rev Epidemiol Sante Publique 2012. [DOI: 10.1016/j.respe.2012.06.153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
44
|
Atramont A, Gilbert F, Lapie-Legouis P, Vercambre MN. Tension au travail selon le modèle de Karasek et recours aux soins de santé mentale, France. Rev Epidemiol Sante Publique 2012. [DOI: 10.1016/j.respe.2012.06.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
45
|
Wilson A, Nyström L, Paci E, Gilbert F, Mann R. E4. Current issues in breast cancer screening. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70055-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
46
|
AlRashidi N, Ahearn T, Jagpal B, Redpath T, Gilbert F. Apparent diffusion coefficient of normal breast tissue during the menstrual cycle at 3 Tesla. Breast Cancer Res 2011. [PMCID: PMC3238242 DOI: 10.1186/bcr2957] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
47
|
Vercambre MN, Gilbert F. Participation à une enquête épidémiologique : facteurs sociodémographiques, de morbidité et d’utilisation du système de soins (France). Rev Epidemiol Sante Publique 2011. [DOI: 10.1016/j.respe.2011.02.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022] Open
|
48
|
Ratkevicius A, Joyson A, Selmer I, Dhanani T, Grierson C, Tommasi AM, DeVries A, Rauchhaus P, Crowther D, Alesci S, Yaworsky P, Gilbert F, Redpath TW, Brady J, Fearon KCH, Reid DM, Greig CA, Wackerhage H. Serum Concentrations of Myostatin and Myostatin-Interacting Proteins Do Not Differ Between Young and Sarcopenic Elderly Men. J Gerontol A Biol Sci Med Sci 2011; 66:620-6. [DOI: 10.1093/gerona/glr025] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
|
49
|
AlRashidi N, Gagliardi T, Ahearn T, Redpath T, Gilbert F. Effect of region of interest size in quantitative diffusion-weighted magnetic resonance imaging of the breast. Breast Cancer Res 2010. [PMCID: PMC2978836 DOI: 10.1186/bcr2672] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
50
|
Ternent L, MacLennan G, Heys SD, Gilbert F, Vale L. Surveillance following breast cancer: is it cost-effective? Breast Cancer Res 2010. [PMCID: PMC2978822 DOI: 10.1186/bcr2658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|